AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1892190 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 65
Study 6344819 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef lung heparin
Number of subjects: 100
Study 6344819 — intervention group
Group type: COMPARATOR
Intervention: Pork mucosal heparin
Number of subjects: 100
Study 6344819 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of heparin
Number of subjects: 100
Study 31062842 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral neuromuscular training
Number of subjects: 116
Study 31062842 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 116
Study 28828881 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA class ≥2 at 30 days
Number of subjects: 402
Study 28828881 — intervention group
Group type: COMPARATOR
Intervention: NYHA class 1 at 30 days
Number of subjects: 402
Study 28828881 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted hazard ratio for NYHA class ≥2
Number of subjects: 402
Study 26839010 — intervention group
Group type: EXPERIMENTAL
Intervention: Chaihuguizhiganjiang-suanzaoren granule (CSG)
Number of subjects: 258
Study 26839010 — intervention group
Group type: COMPARATOR
Intervention: Placebo granule
Number of subjects: 258
Study 25179065 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 22
Study 22059736 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin/metformin 50/500 mg twice daily (up-titrated to 50/1000 mg twice daily)
Number of subjects: 517
Study 22059736 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone 30 mg per day (up-titrated to 45 mg per day)
Number of subjects: 517
Study 22059736 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin/metformin
Number of subjects: 517
Study 22059736 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 517
Study 20079599 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopy
Number of subjects: 58
Study 20079599 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopy
Number of subjects: 58
Study 20079599 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 58
Study 17204832 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 0
Study 17204832 — intervention group
Group type: COMPARATOR
Intervention: Renal dysfunction
Number of subjects: 0
Study 17204832 — intervention group
Group type: COMPARATOR
Intervention: Increased resting heart rate
Number of subjects: 0
Study 17204832 — intervention group
Group type: COMPARATOR
Intervention: Low diastolic blood pressure
Number of subjects: 0
Study 17204832 — intervention group
Group type: COMPARATOR
Intervention: Prolonged QRS duration
Number of subjects: 0
Study 15229009 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clindamycin
Number of subjects: 494
Study 15229009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 494
Study 12461339 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard isolation techniques in a mycology laboratory
Number of subjects: 45
Study 11712626 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (Remeron)
Number of subjects: 28
Study 8994489 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot position error during walking with thin, hard soles
Number of subjects: 26
Study 8994489 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot position error related to stability
Number of subjects: 26
Study 8994489 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot position error related to midsole thickness
Number of subjects: 26
Study 8994489 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot position error related to midsole hardness
Number of subjects: 26
Study 8994489 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot position error correlates with perceived maximum supination
Number of subjects: 26
Study 8216604 — intervention group
Group type: EXPERIMENTAL
Intervention: Stack splint
Number of subjects: 60
Study 8216604 — intervention group
Group type: COMPARATOR
Intervention: Custom‐made padded aluminium alloy malleable finger splint
Number of subjects: 60
Study 3551695 — intervention group
Group type: EXPERIMENTAL
Intervention: pantethine
Number of subjects: 10
Study 29606480 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery programme for ICU survivors
Number of subjects: 181
Study 29606480 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 181
Study 27903997 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 52
Study 27903997 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 52
Study 24738695 — intervention group
Group type: EXPERIMENTAL
Intervention: Canephron N administered with standard antidiabetic therapy and ACE inhibitor
Number of subjects: 59
Study 24738695 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy and ACE inhibitor alone
Number of subjects: 59
Study 24738695 — intervention group
Group type: EXPERIMENTAL
Intervention: Canephron N
Number of subjects: 59
Study 23744760 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy (Arm A)
Number of subjects: 2318
Study 23744760 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy with sequential trastuzumab (Arm B)
Number of subjects: 2318
Study 23744760 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy with concurrent trastuzumab (Arm C)
Number of subjects: 2318
Study 23744760 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence sHER2 levels ≥15 ng/mL
Number of subjects: 2318
Study 19488866 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of BCR/ABL translocation
Number of subjects: 70
Study 19488866 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of MLL/AF4 translocation
Number of subjects: 70
Study 19488866 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of TEL/AML1 translocation
Number of subjects: 70
Study 19488866 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of E2A/PBX1 translocation
Number of subjects: 70
Study 18378744 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive users (77 women)
Number of subjects: 277
Study 18378744 — intervention group
Group type: COMPARATOR
Intervention: Non-oral contraceptive users (200 women)
Number of subjects: 277
Study 16181541 — intervention group
Group type: EXPERIMENTAL
Intervention: Yinxing Damo (YXDM) combined with Betahistine Hydrochloride Injection (BHI), intravenous dripping, once a day for 14 days.
Number of subjects: 90
Study 16181541 — intervention group
Group type: COMPARATOR
Intervention: Xueshuantong and Betahistine Hydrochloride Injection (BHI), intravenous dripping, once daily for 14 days.
Number of subjects: 90
Study 12907285 — intervention group
Group type: EXPERIMENTAL
Intervention: MCCh granules containing 80% MCCh of 150 kDa M(w) with furosemide (40 mg)
Number of subjects: 0
Study 12907285 — intervention group
Group type: EXPERIMENTAL
Intervention: MCCh granules containing 240 kDa M(w)
Number of subjects: 0
Study 12907285 — intervention group
Group type: EXPERIMENTAL
Intervention: MCCh formulations
Number of subjects: 0
Study 12907285 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro release rate of furosemide
Number of subjects: 0
Study 18425653 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief physician-delivered physical activity counseling
Number of subjects: 355
Study 18425653 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 355
Study 8692740 — intervention group
Group type: COMPARATOR
Intervention: Zalcitabine alone
Number of subjects: 12
Study 8692740 — intervention group
Group type: EXPERIMENTAL
Intervention: Zalcitabine with probenecid
Number of subjects: 12
Study 1650104 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemosorption (HS)
Number of subjects: 79
Study 1650104 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 79
Study 30374754 — intervention group
Group type: EXPERIMENTAL
Intervention: SNIPPV
Number of subjects: 9
Study 30374754 — intervention group
Group type: COMPARATOR
Intervention: HHHFNC
Number of subjects: 9
Study 28875955 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 233
Study 27567125 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 60×(8s at 77-85% HRmax, 12s of active recovery), 2 days/week for 16 weeks
Number of subjects: 17
Study 27567125 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT) - 40 min at 55-60% of individual HRR, 2 days/week for 16 weeks
Number of subjects: 17
Study 24927607 — intervention group
Group type: EXPERIMENTAL
Intervention: Filibuvir 300 mg BID plus pegIFN/ribavirin
Number of subjects: 288
Study 24927607 — intervention group
Group type: EXPERIMENTAL
Intervention: Filibuvir 600 mg BID plus pegIFN/ribavirin
Number of subjects: 288
Study 24927607 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus pegIFN/ribavirin
Number of subjects: 288
Study 22912450 — intervention group
Group type: COMPARATOR
Intervention: Control (standard broiler diet containing monensin)
Number of subjects: 1080
Study 22912450 — intervention group
Group type: COMPARATOR
Intervention: Control + bacitracin methylene disalycylate (BMD)
Number of subjects: 1080
Study 22912450 — intervention group
Group type: EXPERIMENTAL
Intervention: Control + YDC (0.02%, 0.01%, and 0.005% for starter, grower, and finisher)
Number of subjects: 1080
Study 22912450 — intervention group
Group type: COMPARATOR
Intervention: BMD treatment
Number of subjects: 1080
Study 22912450 — intervention group
Group type: EXPERIMENTAL
Intervention: YDC treatment
Number of subjects: 1080
Study 19058190 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U BTX‐A
Number of subjects: 44
Study 19058190 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 U BTX‐A
Number of subjects: 44
Study 19058190 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 44
Study 17456679 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 0.0 mug/mL (C0)
Number of subjects: 80
Study 17456679 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 1.0 mug/mL (C1)
Number of subjects: 80
Study 17456679 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2.0 mug/mL (C2)
Number of subjects: 80
Study 17456679 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4.0 mug/mL (C4)
Number of subjects: 80
Study 17456679 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine groups (C1, C2, C4)
Number of subjects: 80
Study 17456679 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 1.0 mug/mL (C1) and Clonidine 2.0 mug/mL (C2)
Number of subjects: 80
Study 14754652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 116
Study 14754652 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine
Number of subjects: 116
Study 12613329 — intervention group
Group type: EXPERIMENTAL
Intervention: IAHC with fluorodeoxyuridine (FUdR)
Number of subjects: 52
Study 12613329 — intervention group
Group type: COMPARATOR
Intervention: Non-IAHC (control group)
Number of subjects: 52
Study 9839768 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil HCl (5 mg)
Number of subjects: 22
Study 7813672 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance group (DG) practicing movements over a fixed distance (36 degrees) from seven initial positions
Number of subjects: 2
Study 7813672 — intervention group
Group type: EXPERIMENTAL
Intervention: Location group (LG) practicing movements from the same seven initial positions to a fixed final location
Number of subjects: 2
Study 7813672 — intervention group
Group type: COMPARATOR
Intervention: Both groups tested at practiced task with eyes closed and unpracticed task unexpectedly
Number of subjects: 2
Study 2667109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1.5 g/day for seven days
Number of subjects: 200
Study 2667109 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg/day for seven days
Number of subjects: 200
Study 367479 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-convulsive therapy (ECT) - six brief pulse unilateral shocks under conventional anaesthesia and muscle relaxation
Number of subjects: 32
Study 367479 — intervention group
Group type: COMPARATOR
Intervention: Control - same procedure without receiving shocks
Number of subjects: 32
Study 30680611 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein (10 mg) and Zeaxanthin (2 mg) supplement
Number of subjects: 48
Study 30680611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 30990855 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective component of the Mellow Bumps parenting intervention
Number of subjects: 108
Study 30990855 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective exercises
Number of subjects: 108
Study 30990855 — intervention group
Group type: EXPERIMENTAL
Intervention: Group allocation
Number of subjects: 108
Study 28930848 — intervention group
Group type: COMPARATOR
Intervention: Conventional laryngoscope (CL)
Number of subjects: 40
Study 28930848 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath Mac videolaryngoscope (VL)
Number of subjects: 40
Study 28930848 — intervention group
Group type: COMPARATOR
Intervention: Both groups (CL and VL)
Number of subjects: 40
Study 26452308 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Life Therapy (CLT)
Number of subjects: 100
Study 26452308 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study 24068588 — intervention group
Group type: EXPERIMENTAL
Intervention: 22G core biopsy needle (FNB)
Number of subjects: 144
Study 24068588 — intervention group
Group type: COMPARATOR
Intervention: Standard 22G fine needle aspiration (FNA) needle
Number of subjects: 144
Study 21074803 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 372
Study 21074803 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg once daily
Number of subjects: 372
Study 21074803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 19447693 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week circuit training
Number of subjects: 68
Study 19447693 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 16714645 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol at a flow rate of 5 mL/sec
Number of subjects: 97
Study 16714645 — intervention group
Group type: COMPARATOR
Intervention: Iodixanol at a flow rate of 3 mL/sec
Number of subjects: 97
Study 15004324 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrinin (100 microg on alternate days for three weeks followed by two weeks drug-free, repeated three times)
Number of subjects: 105
Study 15004324 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrinin
Number of subjects: 105
Study 11922396 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 1412
Study 11922396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1412
Study 9428993 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl supplementation (3-5 mmol/kg/day at postnatal ages of 8-21 days; 1.5-2.5 mmol/kg/day at 22-35 days)
Number of subjects: 9
Study 9428993 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl supplementation (group S)
Number of subjects: 9
Study 9428993 — intervention group
Group type: COMPARATOR
Intervention: No NaCl supplementation (group NS)
Number of subjects: 9
Study 8275216 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention consisting of a diet with 28% of calories as total fat (< 8% saturated fat, up to 9% polyunsaturated fat, 11% monounsaturated fat) and dietary cholesterol intake less than 75 mg/1000 kcal (< 150 mg/d)
Number of subjects: 663
Study 8275216 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group provided with a packet of general dietary information
Number of subjects: 663
Study 8275216 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 663
Study 2880603 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 141,292 1 mg
Number of subjects: 14
Study 2880603 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 141,292 4 mg
Number of subjects: 14
Study 2880603 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 141,292 (1, 2, and 4 mg)
Number of subjects: 14
Study 2880603 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 5 mg
Number of subjects: 14
Study 30647072 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 0
Study 30647072 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28079793 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental treatments under general anesthesia (GA)
Number of subjects: 0
Study 28079793 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GA treatment)
Number of subjects: 0
Study 28079793 — intervention group
Group type: COMPARATOR
Intervention: Both groups (before treatment)
Number of subjects: 0
Study 28079793 — intervention group
Group type: COMPARATOR
Intervention: Both groups (after treatment)
Number of subjects: 0
Study 26157242 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 150
Study 26157242 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study 23771604 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined SHA and CMHA services
Number of subjects: 644
Study 23771604 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined BSR-COSP and CMHA services
Number of subjects: 644
Study 23771604 — intervention group
Group type: EXPERIMENTAL
Intervention: SHA-CMHA trial
Number of subjects: 644
Study 23771604 — intervention group
Group type: EXPERIMENTAL
Intervention: BSR-COSP-CMHA trial
Number of subjects: 644
Study 23771604 — intervention group
Group type: COMPARATOR
Intervention: Regular CMHA services
Number of subjects: 644
Study 21644306 — intervention group
Group type: EXPERIMENTAL
Intervention: Surround needling plus thin cotton moxibustion
Number of subjects: 80
Study 19842559 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral immune nutrition (EIN) enriched with arginine
Number of subjects: 30
Study 19842559 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral nutrition (EN)
Number of subjects: 30
Study 19842559 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EIN and EN groups
Number of subjects: 30
Study 19842559 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral immune nutrition (EIN)
Number of subjects: 30
Study 16777536 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including Vietnamese‐language media campaign, lay health worker outreach, Vietnamese Pap clinic, patient registry/reminder system, restoration of a government‐funded low-cost screening program, and continuing medical education for Vietnamese physicians
Number of subjects: 2009
Study 16777536 — intervention group
Group type: COMPARATOR
Intervention: Comparison community (Harris County, Texas)
Number of subjects: 2009
Study 15132723 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment (0.5, 1.0, and 1.7 IU/m(2) per day)
Number of subjects: 58
Study 15132723 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose GH treatment
Number of subjects: 58
Study 11532054 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO 750 U/kg per week subcutaneously from day 5 to day 40
Number of subjects: 100
Study 11532054 — intervention group
Group type: COMPARATOR
Intervention: Control (no erythropoietin)
Number of subjects: 100
Study 9625225 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived low control over the stressor
Number of subjects: 0
Study 9625225 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived high control over the stressor
Number of subjects: 0
Study 9625225 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 8156959 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 43
Study 8156959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 3137026 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil i.v. (0.35 +/- 0.15 mg)
Number of subjects: 50
Study 3137026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 27391356 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 50 mg
Number of subjects: 13
Study 27391356 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 100 mg
Number of subjects: 13
Study 27391356 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg
Number of subjects: 13
Study 27391356 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment regimen (TPF-E followed by PA-E with XRT)
Number of subjects: 13
Study 27465189 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle placement within the flexor digitorum profundus
Number of subjects: 48
Study 27465189 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle placement within the flexor digitorum superficialis
Number of subjects: 48
Study 27465189 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle placement outside both flexors and the sheath
Number of subjects: 48
Study 27465189 — intervention group
Group type: EXPERIMENTAL
Intervention: Active range of motion assessment
Number of subjects: 48
Study 27465189 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement
Number of subjects: 48
Study 25085539 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Integrated Motivational Intervention plus Treatment As Usual
Number of subjects: 0
Study 25085539 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual alone
Number of subjects: 0
Study 24373301 — intervention group
Group type: EXPERIMENTAL
Intervention: HAPPY (Healthy and Active Parenting Programme for Early Years) intervention consisting of 12 × 2.5 hr. sessions (6 ante-natal from 24 weeks; 6 postnatal up to 9 months)
Number of subjects: 0
Study 24373301 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 20146063 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV plus low-dose EMP (280 mg/day)
Number of subjects: 57
Study 20146063 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose EMP (560 mg/day)
Number of subjects: 57
Study 18490077 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon-alpha2b and ribavirin for 48 weeks
Number of subjects: 19
Study 16634855 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted naltrexone (50 mg/day)
Number of subjects: 150